Halt Medical closes $15 million financing from American Capital to support commercialization of its newly FDA cleared Acessa System, an alternative to hysterectomy for women with uterine fibroids.
Halt Medical closed a $15 million funding round from American Capital, aimed at commercializing its FDA-cleared Acessa System for treating uterine fibroids.
The Las Vegas, Nev.-based device maker said its Acessa system allows physicians to deliver radiofrequency energy to uterine fibroids through a minimally invasive procedure.
"We are delighted that American Capital, has chosen to once again lead financing for this critical new medical device,"Halt's CEO Jeff Cohen said in prepared remarks. "Furthermore, there was significant participation by existing investors, validating our work to address one of the largest unmet needs in women's health worldwide."
Last November, the FDA cleared Acessa system , the 1st product cleared, which can be used by gynecologists to treat all fibroid symptoms and type, the company said.
Fibroids are the leading global cause of hysterectomy procedures, according to the Centers for Disease Control.
In traditional fibroid surgery, a physician generally must either cut through healthy tissue to access the tumor or remove the uterus entirely, according to Halt Medical.
Cyberonics plans to buy back an additional 1 million shares before the end of fiscal 2015.
Ventana, a Roche Group subsidiary, won 510(k) clearance from the Food & Drug Administration for...
TYRX touts expanded 510(k) clearance for its AIGISRx N antibacterial envelope, now cleared for use...
Wall Street analysts find opportunities for savvy investors looking to take advantage of the fallout...